瑞普生物：公司高度重视股价与创业板指数的拟合情况

Core Viewpoint - The company emphasizes the importance of its stock price alignment with the ChiNext Index, indicating a strong focus on market performance and investor sentiment [1] Financial Performance - In the first half of 2025, the company expects revenue of 1.708 billion yuan and a net profit attributable to shareholders of 257 million yuan, representing year-on-year growth of 20.53% and 57.59% respectively, highlighting robust earnings growth [1] Business Strategy - The company has a solid business layout in "economic animal biological products + pet medical services," which is believed to provide long-term value that the market will recognize [1]